Do GLP-1 Drugs Help Most Where Inflammation Is High? A New SELECT Analysis Already Pushes Back

Semaglutide is sold as a weight-loss drug, yet its heart benefit shows up before most of the weight comes off. That gap invites a bold question. If the drug works mainly by calming inflammation, the people who gain most might include lean older adults who would never be offered it today.

Our research desk proposes that the survival benefit of GLP-1 drugs runs mainly through inflammation, not weight. It predicts that in the SELECT trial, the fall in deaths from any cause will cluster in the top third of baseline C-reactive protein (CRP), the standard blood marker of inflammation. It sets a hazard ratio at or below 0.70 there and at or above 0.90 in the bottom third, after adjusting for weight change.

It gives that SELECT result a 40% chance. It gives a lifespan study in lean ageing mice 30%. It also calls for a new trial in normal-weight adults over 65 with CRP above 3 mg/L.

The trial facts check out. SELECT, published in the New England Journal of Medicine in 2023 by A. Michael Lincoff and colleagues, enrolled 17,604 adults aged 45 or older with heart disease and a body mass index of 27 or more, without diabetes. Weekly semaglutide lowered major heart events by 20% over about 40 months of follow-up.

A 2024 JACC analysis led by Benjamin Scirica reported a 19% lower rate of death from any cause, with fewer deaths from infection driving much of the non-cardiac gap. A 2025 Lancet analysis led by John Deanfield found the heart benefit was independent of starting weight and of weight lost. Only about a third appeared to run through a smaller waist.

The inflammation precedent is also real. In the CANTOS trial, published in 2017 by Paul Ridker and colleagues, canakinumab blocked interleukin-1 beta without changing cholesterol. The 150 mg dose lowered heart events by 15%. A secondary analysis found that people whose CRP fell below 2 mg/L on treatment had 31% lower all-cause death. That grouping happened after randomization, so it can flatter the drug, as the desk itself notes.

The brain pathway holds up too. Daniel Drucker's lab in Toronto showed in mice that GLP-1 receptor activation dampened the inflammatory response to bacterial signals, and that this needed receptors on brain neurons. The paper appeared in Cell Metabolism online in December 2023.

In August 2026, Circulation published a prespecified SELECT analysis of CRP led by Jorge Plutzky, with Ridker among the authors. Semaglutide lowered CRP by 37.8% at two years. That drop appeared within four to eight weeks, before major weight loss, and also in people who lost no weight.

Here is the problem for the hypothesis. Semaglutide lowered heart events across all CRP groups: below 2, between 2 and 10, and 10 or higher. The authors concluded inflammation probably explains part of the benefit, not most of it.

That analysis looked at major heart events, not the all-cause death split the desk predicts. So the exact test is still open. But a benefit present even at low CRP makes a strong concentration in the top third less likely, in our view.

The practical question is who should be first in line. If inflammation were the main engine, a lean 72-year-old with high CRP might gain more than a heavier 50-year-old with low CRP. Current evidence says the drug helps across the board in people with obesity and heart disease. Lean people were not studied at all.

• Tangled routes. Weight loss also lowers CRP, so the two are hard to separate in SELECT. • No lean data. Everyone in SELECT was overweight or obese. • Mouse limits. Drucker's result is a short inflammatory challenge, not a lifespan study. • Partial support. Lower CRP likely contributes. The open question is how much.

• If you have heart disease and overweight, a GLP-1 drug is a reasonable discussion with your doctor. The SELECT evidence is randomized and solid. • If you are lean, there is no trial evidence for using these drugs for longevity. Do not seek them off-label on this basis. • A high-sensitivity CRP test is cheap. Ask whether it adds to your heart-risk picture.

• A SELECT analysis of all-cause death by baseline CRP tertile, adjusted for weight change. • Any trial of a GLP-1 drug in normal-weight older adults with raised inflammation. • Lifespan studies of GLP-1 drugs in lean, genetically diverse ageing mice.

Claim What We Found Tier

NIH Brain-Scan Study Tests a New Tracer for a Suspected Inflammation Enzyme Does Heavy Collagen Production Starve the Enzymes That Keep DNA Methylation in Check? A Testable Idea, With an Earlier Clue Do GLP-1 Drugs Help Most Where Inflammation Is High? A New SELECT Analysis Already Pushes Back Nanoscope's Light-Sensing Eye Gene Therapy: Randomized Macular Degeneration Data Are Promised, Not Yet Seen